Johnson & Johnson (JNJ) Stock Price Prediction

Target vs 52-Week Range

Johnson & Johnson is a global multinational corporation focused on innovative medicines and medical technologies. Its operations are divided into two main segments: Innovative Medicine, which includes therapeutic areas such as oncology, immunology, and neuroscience, and MedTech, encompassing cardiovascular care, orthopaedics, surgery, and vision. For the third quarter of 2026, the company reported sales of $25.399 billion, representing a 5.9% year-over-year increase. However, GAAP net earnings were significantly impacted, falling to $210 million, with diluted EPS at $0.09. This substantial decline was primarily due to a one-time special charge related to the proposed talc litigation resolution, the Firefly Bio acquisition, and a collaboration with Sail Biomedicines. Adjusted diluted EPS for the quarter was $2.59, a 7.5% decrease. Despite these impacts, Johnson & Johnson raised its full-year 2026 guidance, projecting estimated reported sales between $101.0 billion and $101.4 billion, and adjusted diluted EPS between $11.05 and $11.15. Key challenges include the loss of patent exclusivity for Stelara to biosimilars and underperformance in the MedTech segment.

Johnson & Johnson's stock (JNJ) has shown a recent downward trend, moving below its 50-day moving average on September 30, 2026. This indicates a shift from an upward to a downward trajectory. Following a three-day decline, the stock is projected to fall further, with a 40% chance of a continued downward trend. The Aroon Indicator also entered a downward trend on October 12, 2026, suggesting a potentially strong downward move. Short-term forecasts anticipate a continued dip, with the price potentially reaching as low as $248.61 by tomorrow (October 16, 2026).

The AI price target of $274.43 for Johnson & Johnson is situated within a generally optimistic analyst landscape. As of October 15, 2026, the company holds a "Moderate Buy" consensus rating with an average target price of $274.35, while other reports suggest a "Strong Buy" consensus and a median 12-month target of $284. Johnson & Johnson recently delivered strong Q3 2026 results on October 13, 2026, exceeding earnings and revenue expectations and subsequently raising its full-year 2026 guidance. The company projects surpassing $100 billion in annual sales for the first time this year. Key recent product approvals include the OTTAVA Robotic Surgical System and IMAAVY for warm autoimmune hemolytic anemia. The company's robust pipeline, particularly in immunology, oncology, and neuroscience, is expected to drive future growth. It is important to remember that price targets are estimates and not guaranteed outcomes.